Hyliion Holdings heads into its August 12 earnings release with short sellers meaningfully positioned and the stock under fresh pressure.
Short interest has climbed sharply over the past month — the most telling signal heading into the print. At 8.8% of the free float, the short position is notable for a stock at this market cap, and the one-month build of roughly 38% in shares short shows bears added aggressively through July. The jump was concentrated: short interest rose from around 10.5 million shares at end of June to over 15.5 million by early August, a move that coincided with the stock losing ground. The borrow market remains accommodating for new shorts — availability is running at nearly 246%, meaning there are roughly two-and-a-half shares available to borrow for every one already lent out. Cost to borrow has edged up about 14% over the past week to 0.61%, but that remains a very low absolute rate. Bears face little friction entering or maintaining positions.
Options positioning has tilted slightly more defensive into the event. The put/call ratio has crept up to 0.17, about 1.4 standard deviations above its 20-day mean, and has been trending higher for the past two weeks. That said, in absolute terms the ratio is still quite low — well below its 52-week high of 0.20 — so the signal is directional rather than alarming. The stock itself is down roughly 5% over the past month to $3.92, with a 4% loss on the week, suggesting sellers have been active in the run-up.
The analyst picture is thin and dated. Needham initiated coverage in June with a Buy and a $9 target — more than double the current price. That gap looks wide against a stock trading near $4, though it may reflect a longer-duration thesis on hydrogen adoption rather than near-term fundamentals. The ORTEX short score of 61 ranks in the 8th percentile for short score rank within the universe, flagging elevated bearish positioning relative to peers. The ownership structure adds an interesting wrinkle: CEO Thomas Healy holds 18.4% of shares, and the entire C-suite — CEO, CFO, CTO, Chief Commercial Officer, and others — all executed small sell transactions in late May. The sales were modest in dollar terms (the CEO's two-day total was roughly $113,000), and trade significance scores were minimal, so they likely reflect routine plan-based disposals rather than a conviction call. BlackRock added over 2.5 million shares in the latest quarter, and Vanguard Capital Management appears to have initiated a position of 6.4 million shares, providing some institutional ballast on the buy side.
The earnings report will test whether the commercial progress Hyliion has pointed to — including the 191% year-on-year revenue increase cited in recent ORTEX scoring data — can begin to address the fundamental concerns that have drawn a growing short position: persistent losses, negative free cash flow, and a quality score that remains one of the weakest in the sector.
See the live data behind this article on ORTEX.
Open HYLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
